Toggle Side Panel

Treatment option for osteoporosis after menopause

max
MariaPCC 8 August 2024

Over 14,000 people could benefit after the National Institute for Health and Care Excellence (NICE) published guidance recommending abaloparatide as an option for treating osteoporosis after menopause, if there is a very high risk of fracture. Abaloparatide (also called Eladynos and made by Theramex) increases bone density by stimulating the cells that make new bone and this reduces the risk of fracture. It can provide an alternative for people who have not responded to, or cannot tolerate, usual treatment options.

Categories: News

Report

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Invite this member to groups
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .
Keep up to date

Sign up to receive our daily news alerts straight to your inbox. Subscribe to our weekly newsletter containing a summary of the week’s news, blog and vote on our poll.

Weekly Newsletter

Daily news updates

Have a discussion

Help keep the conversation going between meetings by creating a forum to hold discussions with your members. It’s an easy way to manage and communicate with members.

Create a network

Create a network to share documents, knowledge and best practice with your colleagues. Set up a network to keep in touch with other people in your organisation or with shared interest groups across organisational boundaries.

Networks can be open to all or available only to a closed group defined by the administrator.

Join or create a network here.